U.S. Membranous Nephropathy Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

U.S. Membranous Nephropathy Market Segmentation, By Disease Type (Primary Membranous Nephropathy, and Secondary Membranous Nephropathy), Type (Diagnosis, and Treatment), Cause (Autoimmune Disease, Hepatitis B and C, Cancer, NSAID Medications, Others), Population Type (Children,and  Adults), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) - Industry Trends and Forecast to 2032

U.S. Membranous Nephropathy Market Size

• The U.S. membranous nephropathy market size was valued at USD 124.39 million in 2024 and is expected to reach USD 183.78 million by 2032, at a CAGR of 5.00% during the forecast period
• The market growth is largely fueled by the rising incidence of membranous nephropathy, particularly among middle-aged and elderly populations, coupled with an increase in autoimmune disorders, diabetes, and other underlying conditions that contribute to kidney damage. These clinical trends are prompting greater demand for early diagnosis and effective long-term treatment options across the United States
• Furthermore, growing advancements in immunosuppressive therapies, biologics, and precision medicine are establishing targeted treatments as the standard of care for membranous nephropathy. These converging factors are accelerating the uptake of innovative therapeutics and diagnostic tools, thereby significantly boosting the industry's growth

U.S. Membranous Nephropathy Market Analysis

• Immunosuppressive therapies and biologics, such as rituximab and corticosteroids, are increasingly vital components of membranous nephropathy treatment in the U.S., driven by their effectiveness in reducing proteinuria and preserving kidney function in patients with moderate to severe disease. These advanced therapeutics are becoming standard in both hospital-based nephrology care and specialized outpatient clinics
• The escalating demand for targeted treatment options is primarily fueled by the rising prevalence of autoimmune conditions and chronic kidney disease across the U.S., coupled with increasing awareness among healthcare providers and patients regarding early detection and personalized disease management strategies
• U.S. accounted for 41.3% market share in membranous nephropathy market in 2024 within the global landscape, supported by a robust healthcare infrastructure, early adoption of novel therapeutics, and substantial R&D investments by pharmaceutical companies focused on rare renal diseases
• The treatment segment dominated the membranous nephropathy market with a market share of 72.3% in 2024, driven by the widespread use of immunosuppressive therapies and biologics such as rituximab. The increasing clinical adoption of targeted treatments and advancements in therapeutic protocols continue to reinforce the dominance of this segment in managing both primary and secondary membranous nephropathy

Report Scope and U.S. Membranous Nephropathy Market Segmentation    

U.S. Membranous Nephropathy Market Trends

“Increasing Integration of Artificial Intelligence (AI) and Digital Health Technologies”

• A significant and accelerating trend in the U.S. membranous nephropathy market is the increasing integration of artificial intelligence (AI) and digital health technologies to enhance diagnostic precision, treatment personalization, and patient monitoring. This technological shift is reshaping clinical approaches and improving patient outcomes

  • For instance, AI-powered algorithms are being used to analyze kidney biopsy images and electronic health records to facilitate earlier and more accurate diagnosis of membranous nephropathy. Machine learning tools are also aiding clinicians in identifying high-risk patients who may benefit from more aggressive treatment or closer monitoring

• Digital platforms and AI-based applications are enabling remote monitoring of kidney function, proteinuria levels, and treatment adherence. These tools provide real-time data to healthcare providers, allowing timely interventions and better disease management. In addition, predictive analytics models are helping forecast disease progression and treatment responses
• Integration with wearable devices and smart home health technologies offers patients increased convenience in tracking their symptoms and treatment outcomes. Patients can now record vital signs such as blood pressure and urine output, which are crucial in managing membranous nephropathy, through connected health apps linked to clinician dashboards
• This trend toward smarter, tech-enabled care is fundamentally changing expectations for disease management. As a result, pharmaceutical and med-tech companies are investing heavily in AI-driven drug discovery and personalized nephrology solutions to cater to the growing demand for targeted therapies in this domain
• The demand for integrated AI solutions is rapidly increasing in the U.S. membranous nephropathy market, particularly as clinicians and patients seek more efficient, proactive, and individualized management strategies. This offers immense potential for market players to differentiate through innovation in diagnostics, therapeutics, and digital health platforms

U.S. Membranous Nephropathy Market Dynamics

Driver

“Growing Need Due to Rising Disease Burden and Advancements in Diagnostic Capabilities”

• The increasing prevalence of membranous nephropathy (MN) cases in the U.S., particularly among middle-aged and elderly populations, is significantly driving the demand for early diagnosis and effective treatment options. The chronic nature of this autoimmune kidney disorder, coupled with its potential to progress into end-stage renal disease (ESRD), underscores the growing medical need in the market

  • For instance, recent research initiatives and registry data in the U.S. highlight an uptick in MN diagnoses, attributed in part to better clinical awareness and improved diagnostic tools such as kidney biopsies and anti-PLA2R antibody testing. These tools enable more accurate disease classification, timely interventions, and targeted therapy development

• As patients and healthcare providers become more aware of the progressive nature of membranous nephropathy, there is a greater emphasis on long-term disease monitoring and individualized treatment regimens. This growing focus is propelling the adoption of immunosuppressants, biologics, and supportive care options
• Furthermore, the push for precision medicine and the integration of molecular diagnostics are making personalized approaches to MN management more accessible. With increasing research investments in nephrology and autoimmune disease treatment, novel biomarkers and therapeutic targets are being identified, opening new avenues for market players
• The demand for patient-centric, efficient, and proactive disease management solutions is rising across nephrology practices and academic research centers, further supported by favorable reimbursement for biologics and advanced diagnostic procedures

Restraint/Challenge

“Limited Awareness, High Treatment Costs, and Diagnostic Delays”

• Limited awareness of membranous nephropathy among primary care providers and patients remains a significant barrier to early diagnosis and intervention. Because the disease can present with nonspecific symptoms such as edema or proteinuria, it is often misdiagnosed or diagnosed late, resulting in delayed treatment initiation

  • For instance, in community healthcare settings across the U.S., access to nephrology specialists and advanced diagnostics such as renal biopsies and serological markers (such as, anti-PLA2R) may be inconsistent, especially in rural or underserved areas. This can lead to clinical delays and suboptimal outcomes

• In addition, the high cost of treatment, particularly for biologic therapies and long-term immunosuppressive regimens, can be prohibitive for some patients. Insurance limitations, copay requirements, and gaps in reimbursement for diagnostic tests further contribute to financial burdens, potentially deterring patients from pursuing necessary treatment
• While government initiatives and advocacy groups are working to improve awareness and access, the perceived complexity and cost of MN management can still hinder widespread diagnosis and therapy adoption
• Overcoming these challenges through improved clinician education, expanded coverage for diagnostic tools, and development of cost-effective therapeutic options will be essential to ensure equitable access and drive sustained growth in the U.S. membranous nephropathy market

U.S. Membranous Nephropathy Market Scope

The market is segmented on the basis of disease type, type, cause, population type, end user, and distribution channel.

• By Disease Type

On the basis of disease type, the U.S. membranous nephropathy market is segmented into primary membranous nephropathy and secondary membranous nephropathy. The primary membranous nephropathy segment held the largest revenue share of 67.8% in 2024, driven by high prevalence and increased use of PLA2R antibody testing.

The secondary membranous nephropathy segment is expected to witness the fastest CAGR from 2025 to 2032, fueled by rising associated conditions such as hepatitis and autoimmune disorders.

• By Type

On the basis of type, the U.S. membranous nephropathy market is segmented into diagnosis and treatment. The treatment segment dominated with a market share of 72.3% in 2024, due to the extensive use of immunosuppressive drugs and biologics such as rituximab.

The diagnosis segment is anticipated to register the fastest CAGR of 7.5% during 2025–2032, supported by growing demand for early detection using biomarkers and biopsy tools.

• By Cause

On the basis of cuse, the U.S. membranous nephropathy market is segmented into autoimmune disease, hepatitis B and C, cancer, NSAID medications, and others. Autoimmune disease held the largest share of 48.6% in 2024, reflecting its leading role in disease etiology.

NSAID medications are projected to grow at the highest CAGR of 8.1% from 2025 to 2032, due to rising use of over-the-counter painkillers and increased awareness of nephrotoxicity.

• By Population Type

On the basis of population type, the U.S. membranous nephropathy market is segmented into children and adults. The adults segment accounted for 83.4% of the market share in 2024, since MN is most frequently diagnosed in adults aged 40–70 years.

The children segment is expected to witness a CAGR of 6.3% from 2025 to 2032, attributed to improved pediatric diagnostics and increased clinical focus on early-stage kidney disorders.

• By End User

On the basis of end user, the U.S. membranous nephropathy market is segmented into hospitals, specialty clinics, home healthcare, and others. Hospitals dominated the segment with a market share of 61.5% in 2024, supported by inpatient treatment demand and access to full nephrology services.

Home healthcare is expected to witness the fastest CAGR from 2025 to 2032, driven by remote monitoring technologies and a shift toward decentralized care for chronic conditions.

• By Distribution Channel

On the basis of distribution channel, the U.S. membranous nephropathy market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others. Hospital pharmacy accounted for the highest share of 39.7% in 2024, attributed to centralized drug supply for immunosuppressive treatments.

The online pharmacy segment is forecast to grow at the fastest CAGR of 8.6% from 2025 to 2032, fueled by rising digital health adoption and convenience in medication access for chronic disease patients.

U.S. Membranous Nephropathy Market Regional Analysis

• The U.S. membranous nephropathy market captured the largest revenue share of 41.3% within North America in 2024, driven by advanced healthcare infrastructure, strong presence of key pharmaceutical companies, and high disease awareness. The country benefits from widespread availability of diagnostic tools such as kidney biopsies and anti-PLA2R antibody testing, which support accurate and timely diagnosis of membranous nephropathy
• Furthermore, the U.S. market is experiencing a significant shift towards personalized treatment approaches, including the adoption of biologics and immunosuppressive therapies tailored to individual patient profiles. Favorable reimbursement policies and a growing patient preference for non-invasive monitoring solutions are also contributing to the expansion of treatment options
• The increasing incidence of autoimmune diseases and chronic kidney conditions among adults—particularly those aged 40 to 70—is boosting demand for both diagnosis and long-term care. In addition, initiatives by research institutions and pharmaceutical companies to develop targeted therapies and novel biomarkers continue to strengthen the pipeline and open new growth avenues

U.S. Membranous Nephropathy Market Share

The U.S. membranous nephropathy industry is primarily led by well-established companies, including:

• Solco Healthcare (U.S.)
• ALMATICA PHARMA LLC (U.S.)
• Zydus Pharmaceuticals, Inc. (U.S.)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Viatris Inc. (U.S.)
• Avet Pharmaceuticals Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Lupin Pharmaceuticals, Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Hikma Pharmaceuticals PLC (Jordan)
• Accord Healthcare (U.K.)
• Sun Pharmaceutical Industries Ltd. (India)
• CareDx, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Azurity Pharmaceuticals, Inc. (U.S.)
• Fresenius SE & Co. KGaA (Germany)
• Strides Pharma Science Limited (India)
• Alembic Pharmaceuticals Limited (India)
• AbbVie Inc. (U.S.)

Latest Developments in U.S. Membranous Nephropathy Market

• In March 2025, the University of California, San Francisco (UCSF) initiated a Phase 2 clinical trial to evaluate the combination of Belimumab and Rituximab for the treatment of primary membranous nephropathy. This groundbreaking study aims to explore whether dual B-cell inhibition can improve disease remission rates and reduce relapse in comparison to monotherapy. The trial underscores UCSF’s leadership in nephrology research and highlights the growing shift toward biologic combination therapies for complex kidney diseases in the U.S.
• In February 2025, BeiGene USA Inc. announced the launch of a Phase 2 trial to assess the safety and efficacy of Zanubrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in patients with primary membranous nephropathy. This study marks one of the first applications of BTK inhibitors in autoimmune kidney disorders, showcasing the potential for targeted immunomodulation in nephrology. The move represents BeiGene’s expanding U.S. research footprint and innovation in kidney disease therapeutics

SKU-60681